Source: International Congress 2018 – Notable Studies in Asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Albers (Research Triangle Park, United States of America), S. Khurana (Rochester, United States of America), E. Bradford (Research Triangle Park, United States of America), M. Gilson (Stockley Park, Uxbridge, United Kingdom), R. Price (Stevenage, United Kingdom), G. Brusselle (Ghent, Belgium), E. Bel (Amsterdam, Netherlands), J. Fitzgerald (Vancouver, Canada), M. Masoli (Plymouth, United Kingdom), S. Korn (Mainz, Germany), M. Humbert (Le Kremlin-Bicêtre, France). Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX. 3566

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021